🔎 Trials Near Me

Home › Familial Primary Pulmonary Hypertension › NCT01884051

Hormonal, Metabolic, and Signaling Interactions in PAH

RecruitingObservational studyHealthy volunteers welcome

Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension

Who can join

Up to age 90 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

Project 1

Inclusion:

1. Diagnosis of IPAH (idiopathic pulmonary arterial hypertension), HPAH (heritable pulmonary arterial hypertension), or APAH (associated pulmonary arterial hypertension), family members of affected persons
2. Age 0-90, age 12-90 for skin biopsy

Exclusion:

1. Other diagnosis
2. Age greater than 90, age less than 12 or greater than 90 for skin biopsy

Project 2

Inclusion:

1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
2. 0-90
3. Subjects with reasonably easy access to clinic for blood collection and other testing
4. Subject able to tolerate fasting state prior to sample collection and EndoPAT (endothelial function assessment) testing

Exclusion:

1. Other diagnosis
2. 0-90
3. Subjects with difficulty reaching clinic for blood collection and other testing
4. Subjects unable to tolerate fasting state

Project 3

Inclusion:

1. Diagnosis of IPAH, HPAH, or APAH, family members of affected persons
2. 7-90

Exclusion:

1. Other diagnosis
2. Age less than 7 or greater than 90

   \-

   Exclusion Criteria:

   \-

About the study

Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.

Sponsor: Vanderbilt University Medical Center · Participants: 1,899 · Started: 2012-09

Contact the study team

Official record on ClinicalTrials.gov — NCT01884051

Locations in the U.S.

TennesseeVanderbilt University Medical Center, Nashville

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.